170229-13-7

Upstream product

• 625-38-7 but-3-enoic acid 
• 52707-54-7 4-cyanobenzaldehyde oxime 
• 52707-59-2 4-Cyanobenzaldoxime 
• 123476-70-0 (Z)-4-cyano-N-hydroxybenzimidoyl chloride 
• 105-07-7 4-cyanobenzaldehyde 
• 170229-12-6 [3-(4-Cyano-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetic acid methyl ester 

Downstream Products

• 170229-14-8 3-{2-[3-(4-Cyano-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-propionic acid ethyl ester 
• 181023-08-5 (R)-2-[3-(4-cyanophenyl)-4,5-dihydroisoxazol-5-yl]acetic acid 
• 170726-81-5 [3-(4-cyano-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetic acid 
• 213968-12-8 [3-(4-cyano-phenyl)-4,5-dihydro-isoxazol-5-yl]-thioacetic acid ethyl ester 
• 170726-53-1 (R,S)-3-(4-{[N-(dimethylethoxycarbonyl)imino]aminomethyl}phenyl)-4,5-dihydro-5-isoxazoleacetic acid 
• 170726-52-0 methyl (R,S)-3-(4-{[N-(dimethylethoxycarbonyl)imino]aminomethyl}phenyl)-4,5-dihydro-5-isoxazoleacetate 
• 190446-75-4 (S)-3-{2-[3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-methoxycarbonylamino-propionic acid methyl ester 
• 190446-44-7 methyl 3-[({3-[4-({[(1,1-dimethylethoxy)carbonyl]amino}iminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl}acetyl)amino]-N-[(phenylmethoxy)carbonyl]-L-alanine 
• 190447-78-0 methyl 3-[({3-[4-({[(1,1-dimethylethoxy)carbonyl]amino}iminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl}acetyl)methylamino]-L-alanine 

Relevant academic research and scientific papers

Isoxazoline and isoxazole fibrinogen receptor antagonists

This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Isoxazoline fibrinogen receptor antagonists

This invention relates to improved isoxazoline compounds including, but not limited to N2 -(3,5-dimethylisoxazole-4-sulfonyl)-N3 -?3-(4-amidinophenyl)isoxazolin-5(R)-ylacetyl!-(S)-2,3-diaminopropionic acid, which are useful as antago

Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors

Factor Xa is an important serine protease in the blood coagulation cascade. It generates thrombin and holds the central position that links the intrinsic and extrinsic activation mechanism in the final common pathway of coagulation. Therefore, inhibition

Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists

Using isoxazoline XR299 (la) as a starting point for the design of highly potent, long-duration GPIIb/IIIa antagonists, the effect of placing lipophilic substituents at positions α and β to the carboxylate moiety was evaluated. Of the compounds studied, it was found that the n-butyl carbamate 24u1,2 exhibited superior potency and duration of ex vivo antiplatelet effects in dogs. Replacement of the benzamidin-4-yl moiety with alternative basic groups, elimination of the isoxazoline stereocenter, and reversal of the orientation of the isoxazoline ring resulted in lowered potency and/or duration of action.

Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists

Using the isoxazoline as a common structural feature, three series of glycoprotein IIb/IIIa receptor antagonists were evaluated, culminating in the discovery of XR299 (30). In an in vitro assay of platelet inhibition, XR299 had an IC50 of 0.24 μM and was a potent antiplatelet agent when dosed intravenously in a canine model. It was shown through X-ray studies of the cinchonidine salt 49 that the receptor required the 5(R)-stereochemistry for high potency. The ethyl ester prodrug of XR299, XR300 (29), was orally active in the dog.